GDA

GDA integrates genomic and pharmacological data to enable integrative analysis in cancer research, combining drug response data for over 50,800 compounds with mutation and gene expression profiles across 73 cancer cell lines.

Key Features:

• Data integration: Integrates drug response data for over 50,800 compounds with mutation and gene expression profiles across 73 cancer cell lines.
• Modular architecture: Employs a modular architecture that enables complex, configurable analyses.
• Compound–genotype association analysis: Identifies compounds that are active against cancer cell lines with specific genomic backgrounds.
• Response profiling: Determines mutational or transcriptional status of cells in response to particular compounds.
• Public data augmentation: Supplements integrated results with information from public repositories.
• Biomarker and compound discovery: Supports discovery of genetic markers of drug sensitivity and identification of clinically relevant anticancer compounds.

Scientific Applications:

• Personalized targeted therapy research: Links genomic traits to drug responses to inform hypotheses for targeted therapies.
• Drug repurposing: Facilitates identification of existing compounds with potential anticancer activity in specific genomic contexts.
• Pharmacogenomics and biomarker discovery: Enables pharmacogenomic analyses and discovery of genetic markers of drug sensitivity across cancer cell lines.

Methodology:

A modular architecture integrates drug response data with mutation and gene expression profiles to perform analyses that identify compound–genotype associations and determine mutational or transcriptional responses to compounds.